Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
New and Emerging Targeted Topical and Systemic Drugs for Immunemediated...
share announcement

New and Emerging Targeted Topical and Systemic Drugs for Immunemediated Cutaneous Diseases

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".

Deadline for manuscript submissions: 31 October 2024 | Viewed by 3675

Special Issue Editor

Prof. Dr. Tiago Torres

E-Mail Website
Guest Editor
1. Department of Dermatology, Centro Hospitalar Universitário do Porto, Porto, Portugal
2. Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal
Interests: psoriasis; atopic dermatitis; immunemediated diseases
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Immune-mediated cutaneous diseases are a group of disorders that arise due to abnormal immune system functioning, affecting a significant number of individuals worldwide. These diseases can significantly impact patients' quality of life and cause physical and emotional distress. The pathogenesis of conditions such as psoriasis, atopic dermatitis, alopecia areata, vitiligo, hidradenitis suppurativa, prurigo nodularis, and others involve complex interactions between genetic susceptibility, environmental triggers, and immune system dysregulation.

The understanding of the mechanisms behind these diseases has led to the development of targeted topical and systemic therapies, including biologic agents and small molecules. These therapies work by targeting specific cytokines and signaling pathways involved in disease pathogenesis.

This Special Issue aims to review new and emerging therapies for immune-mediated cutaneous diseases, including psoriasis, atopic dermatitis, alopecia areata, vitiligo, and hidradenitis suppurativa. Articles focused on the latest advances in targeted therapies, as well as promising therapies in development, including novel small molecules and biologic agents, are welcome. Our goal is to provide clinicians and researchers with a comprehensive understanding of the current state of the art in the treatment of these conditions.

Prof. Dr. Tiago Torres
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • psoriasis
  • atopic dermatitis
  • alopecia areata
  • vitiligo
  • hidradenitis supurativa
  • prurigo nodularis
  • urticaria
  • cutaneous lupus
  • drug targeting

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

18 pages, 1071 KiB  
Review
Phosphodiesterase-4 Inhibition in the Management of Psoriasis
by Erika L. Crowley and Melinda J. Gooderham
Pharmaceutics 2024, 16(1), 23; https://doi.org/10.3390/pharmaceutics16010023 - 22 Dec 2023
Cited by 1 | Viewed by 1269
Abstract
Psoriasis is a common chronic immune-mediated disease with many comorbidities and impacts on quality of life. Among the treatments for psoriasis, phosphodiesterase-4 (PDE4) inhibitors are emerging with expanding options. PDE4 inhibitors play a pivotal role in the inflammatory cascade by degrading cyclic adenosine [...] Read more.
Psoriasis is a common chronic immune-mediated disease with many comorbidities and impacts on quality of life. Among the treatments for psoriasis, phosphodiesterase-4 (PDE4) inhibitors are emerging with expanding options. PDE4 inhibitors play a pivotal role in the inflammatory cascade by degrading cyclic adenosine monophosphate (cAMP), contributing to pro-inflammatory mediator production. Apremilast, an oral PDE4 inhibitor, is approved for psoriasis. While effective, its adverse effects can limit its utility. Roflumilast, a topical PDE4 inhibitor, was also recently approved for psoriasis and shows promise in clinical trials. Crisaborole, a PDE4 inhibitor approved for atopic dermatitis, has also been studied in psoriasis. This review summarizes evidence from randomized clinical trials regarding the efficacy and safety of PDE4 inhibitors in psoriasis treatment. By highlighting their potential benefits and limitations, this review provides valuable insights for clinicians and researchers aiming to optimize psoriasis management. Full article
(This article belongs to the Special Issue New and Emerging Targeted Topical and Systemic Drugs for Immunemediated Cutaneous Diseases)
►▼ Show Figures

Figure 1

14 pages, 1226 KiB  
Review
IL-17 Inhibition: A Valid Therapeutic Strategy in the Management of Hidradenitis Suppurativa
by Dalma Malvaso, Laura Calabrese, Andrea Chiricozzi, Flaminia Antonelli, Giulia Coscarella, Pietro Rubegni and Ketty Peris
Pharmaceutics 2023, 15(10), 2450; https://doi.org/10.3390/pharmaceutics15102450 - 11 Oct 2023
Cited by 2 | Viewed by 2016
Abstract
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with a significant negative impact on the quality of life of patients. To date, the therapeutic landscape for the management of the disease has been extremely limited, resulting in a profound unmet need. Indeed, [...] Read more.
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with a significant negative impact on the quality of life of patients. To date, the therapeutic landscape for the management of the disease has been extremely limited, resulting in a profound unmet need. Indeed, adalimumab, an anti-tumor necrosis factor (TNF)-α monoclonal antibody, is the only approved biologic agent for HS, obtaining a therapeutic response in only 50% of HS patients. Numerous clinical trials are currently ongoing to test novel therapeutic targets in HS. The IL-17-mediated cascade is the target of several biologic agents that have shown efficacy and safety in treating moderate-to-severe HS. Both bimekizumab and secukinumab, targeting IL-17 in different manners, have successfully completed phase III trials with promising results; the latter has recently been approved by EMA for the treatment of HS. The aim of this review is to summarize the current state of knowledge concerning the relevant role of IL-17 in HS pathogenesis, highlighting the key clinical evidence of anti-IL-17 agents in the treatment of this disease. Full article
(This article belongs to the Special Issue New and Emerging Targeted Topical and Systemic Drugs for Immunemediated Cutaneous Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop